Results 181 to 190 of about 302,063 (326)

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

Intelligent Thermo‐Self‐Limited Magnetothermia with Heat‐Triggered TERT Silencing for Precision Synergetic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Telomerase reverse transcriptase (TERT) mRNA induces DNA self‐assembly in cancer cells, boosting the nanoplatform's magnetothermal properties. This magnetothermia then activates the Hsp70 promoter, initiating siRNA synthesis to silence the TERT gene, enhancing cancer treatment.
Liang Zhang   +9 more
wiley   +1 more source

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang   +7 more
wiley   +1 more source

Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis

open access: yesAdvanced Science, EarlyView.
Oral nanoCEL exhibits effective intestinal targeting of antigen‐presenting cells and restores the Th17/Treg balance in lymph nodes and spleen, ultimately protecting the blood‐retinal barrier by inhibiting peripheral immune cell infiltration and suppressing retinal glial cell activation.
Jinrun Chen   +13 more
wiley   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

open access: yesAdvanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy